Advanced Her2 Expressing Biliary Tract Cancer clinical trials

Explore recruiting advanced her2 expressing biliary tract cancer clinical trials.

Recruiting advanced her2 expressing biliary tract cancer studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Advanced Her2 Expressing Biliary Tract Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

DESTINY-Biliary Tract Cancer-01: A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig versus Standard-of-Care Gemcitabine, Cisplatin, and Durvalumab for First Line Locally Advanced or Metastatic HER2-expressing Biliary Tract Cancer.

Czechia, Germany, Belgium, Italy, Spain, Poland +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Advanced Her2 Expressing Biliary Tract Cancer trials by city

Advanced Her2 Expressing Biliary Tract Cancer clinical trials

Recruiting advanced her2 expressing biliary tract cancer studies right now

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer

Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors

Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib as First-Line Therapy for Advanced HER2-Positive/HER2-Low Biliary Tract Cancer

Also recruiting in Europe

DESTINY-Biliary Tract Cancer-01: A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig versus Standard-of-Care Gemcitabine, Cisplatin, and Durvalumab for First Line Locally Advanced or Metastatic HER2-expressing Biliary Tract Cancer.

Advanced Her2 Expressing Biliary Tract Cancer trials by city

Other conditions